Department of Paediatrics, Emma Children's Hospital-AMC.
Department of Paediatrics, VU University Medical Center, Amsterdam, The Netherlands.
J Pediatr Gastroenterol Nutr. 2018 Jul;67(1):103-122. doi: 10.1097/MPG.0000000000001897.
Several randomized controlled trials (RCTs) on the use of probiotics to reduce morbidity and mortality in preterm infants have provided inconsistent results. Although meta-analyses that group all of the used strains together are suggesting efficacy, it is not possible to determine the most effective strain that is more relevant to the clinician. We therefore used a network meta-analysis (NMA) approach to identify strains with greatest efficacy.
A PubMed search identified placebo-controlled or head-to-head RCTs investigating probiotics in preterm infants. From trials that recorded mortality, necrotizing enterocolitis, late-onset sepsis, or time until full enteral feeding as outcomes, data were extracted and Bayesian hierarchical random-effects models were run to construct a NMA.
Fifty-one RCTs involving 11,231 preterm infants were included. Most strains or combinations of strains were only studied in one or a few RCTs. Only 3 of 25 studied probiotic treatment combinations showed significant reduction in mortality rates. Seven treatments reduced necrotizing enterocolitis incidence, 2 reduced late-onset sepsis, and 3 reduced time until full enteral feeding. There was no clear overlap of strains, which were effective on multiple outcome domains.
This NMA showed efficacy in reducing mortality and morbidity only in a minority of the studied strains or combinations. This may be due to an inadequate number, or size, of RCTs, or due to a true lack of effect for certain species. Further large and adequately powered RCTs using strains with the greatest apparent efficacy will be needed to more precisely define optimal treatment strategies.
几项关于益生菌用于降低早产儿发病率和死亡率的随机对照试验(RCT)得出了不一致的结果。虽然将所有使用的菌株分组进行的荟萃分析表明有疗效,但无法确定与临床医生更相关的最有效菌株。因此,我们使用网络荟萃分析(NMA)方法来确定疗效最佳的菌株。
通过 PubMed 搜索,确定了安慰剂对照或头对头 RCT,以调查早产儿中的益生菌。从记录死亡率、坏死性小肠结肠炎、晚发性败血症或完全肠内喂养时间作为结局的试验中,提取数据并运行贝叶斯分层随机效应模型,构建 NMA。
共纳入 51 项 RCT,涉及 11231 名早产儿。大多数菌株或菌株组合仅在一项或几项 RCT 中进行了研究。只有 25 种研究的益生菌治疗组合中的 3 种显示出死亡率的显著降低。7 种治疗方法降低了坏死性小肠结肠炎的发生率,2 种降低了晚发性败血症,3 种降低了完全肠内喂养的时间。没有明显的菌株重叠,这些菌株在多个结局领域都有效果。
这项 NMA 仅显示出少数研究的菌株或组合在降低死亡率和发病率方面有疗效。这可能是由于 RCT 的数量或规模不足,或者某些物种确实没有效果。需要进一步进行大型且足够有力的 RCT,使用疗效最明显的菌株,以更精确地确定最佳治疗策略。